Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Tak PP, et al. Among authors: nasonov e. Arthritis Rheum. 2008 Jan;58(1):61-72. doi: 10.1002/art.23178. Arthritis Rheum. 2008. PMID: 18163485 Free article. Clinical Trial.
An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I. Pena-Rossi C, et al. Among authors: nasonov e. Lupus. 2009 May;18(6):547-55. doi: 10.1177/0961203309102803. Lupus. 2009. PMID: 19395457 Free PMC article. Clinical Trial.
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R. Genovese MC, et al. Among authors: nasonov e. Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463. Arthritis Rheum. 2011. PMID: 21618201 Free PMC article. Clinical Trial.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Among authors: nasonov el. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register. Chatzidionysiou K, et al. Among authors: nasonov e. Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Arthritis Res Ther. 2016. PMID: 26883119 Free PMC article.
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P. Westhovens R, et al. Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17. Ann Rheum Dis. 2013. PMID: 23161899 Clinical Trial.
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li H, Schulman SL, Raber S, Zuckerman A, Isaacs JD. Kremer JM, et al. Arthritis Res Ther. 2015 Apr 6;17(1):95. doi: 10.1186/s13075-015-0612-7. Arthritis Res Ther. 2015. PMID: 25889308 Free PMC article. Clinical Trial.
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R. Genovese MC, et al. Among authors: nasonov e. J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15. J Rheumatol. 2018. PMID: 29657147 Free article. Clinical Trial.
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R. Genovese MC, et al. Among authors: nasonov e. J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584926 Free article. Clinical Trial.
511 results